Physician profile
Eric Costanzo
NPI 1700977923
$3,881.99
in general payments reported to CMS, 2019-2025
29 companies · $748 in 2025
The $748 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $748 · 2020: $112 · 2021: $69.99 · 2022: $257 · 2023: $1,013 · 2024: $934 · 2025: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,604 · Education: $91.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,603.83 |
| Education | $91.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $719.07 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und, (8874) Incourage |
| Astrazeneca Pharmaceuticals Lp | $599.60 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Ambu INC. | $555.23 | 2022-2024 | |
| Glaxosmithkline, LLC. | $338.18 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.87 | 2019-2025 | Ofev, Jascayd |
| Regeneron Healthcare Solutions, INC. | $180.56 | 2019-2025 | Dupixent |
| Insmed, INC. | $146.87 | 2019-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $141.01 | 2019-2024 | Yupelri |
| Pfizer INC. | $111.79 | 2022-2024 | |
| United Therapeutics Corporation | $94.04 | 2023-2025 | Tyvaso |
| Amgen INC. | $92.89 | 2023-2025 | Tezspire |
| Actelion Pharmaceuticals US, INC. | $79.88 | 2019-2024 | Uptravi |
| Genzyme Corporation | $73.80 | 2019-2025 | |
| Inspire Medical Systems, INC. | $72.04 | 2023-2024 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $59.66 | 2023-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $42.85 | 2019-2024 | Prolastin-C Liquid |
| Abbvie INC. | $34.15 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $29.15 | 2020-2021 | |
| Boston Scientific Corporation | $28.87 | 2022 | |
| Viatris Specialty LLC | $23.73 | 2025 | Yupelri |
| Electromed, INC. | $22.99 | 2019 | |
| Daxor Corporation | $19.33 | 2025 | Bva-100 |
| Merck Sharp & Dohme LLC | $19.30 | 2024 | Winrevair |
| Harmony Biosciences LLC | $16.20 | 2025 | |
| Melinta Therapeutics, LLC | $14.93 | 2019 | |
| Verona Pharma, INC. | $14.86 | 2025 | Ohtuvayre |
| Baxter Healthcare | $13.73 | 2025 | |
| Sunovion Pharmaceuticals INC. | $12.42 | 2020 | |
| Apria Healthcare LLC | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Costanzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.